Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dasatinib 100 mg in Healthy Colombian Subjects
NCT05944783Phase 4Not yet recruiting
- Sponsor
- CAIMED
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dasatinib in multiple myeloma (MM), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by CAIMED. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dasatinib
03
Conditions
multiple myeloma (MM)chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05944783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944783.